Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00255359 |
|
Recruitment Status :
Withdrawn
First Posted : November 18, 2005
Last Update Posted : November 6, 2007
|
Sponsor:
Hadassah Medical Organization
Collaborator:
XTL Biopharmaceuticals
Information provided by:
Hadassah Medical Organization
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Primary Completion Date : | No date given |
| Study Completion Date : | November 2007 |